ShortCuts-This Week in the Journals

February 25, 2008
ShortCuts-This Week in the Journals

Commentary by Danise Schiliro-Chuang MD, NYU Chief Resident 

Hello and welcome to this week’s shortcuts. Let’s jump right to what’s new in the journals.

Two large, multicenter, randomized controlled studies published in the February 13 issue of JAMA show that patients with acute lung injury may benefit from higher positive end-expiratory pressures (PEEP). In the first study by Meade et al. the control arm received low target tidal volumes of 6ml/kg, plateau airway pressures not exceeding 30cm H20 and conventional levels of PEEP.…

Read more »

Bedside Rounds Series: Goiter

February 21, 2008
Bedside Rounds Series: Goiter

Commentary by Kristin Remus MD, PGY-3, and Judith Brenner MD, Associate Program Director, NYU Internal Medicine Residency Program

The purpose of the physical diagnosis series is to review the origins, pathophysiology and actual techniques of common physical diagnoses. Our hopes are to renew interest in an area of medicine that is occasionally overlooked due to the current use of laboratory values and imaging tests frequently used to make a diagnosis.

Goiter
In the industrialized world, enlarged thyroid, or “goiter”, occurs in 10% of women and…

Read more »

Measles Alert!

February 20, 2008
Measles Alert!

Commentary by Rosemary Adamson MD, PGY-2

Be on the look-out for measles! New York City’s Department of Health and Mental Hygiene (DOHMH) issued a measles alert at the end of last November because there were 5 confirmed cases of measles being imported from abroad in 2007 to NYC. The DOHMH wished to raise healthcare provider awareness of measles, especially in travelers. Coming from the UK, this alert is close to my heart, as Britain has been battling with reduced uptake of the MMR vaccine and consequent…

Read more »

ShortCuts-This Week in the Journals

February 18, 2008
ShortCuts-This Week in the Journals

Commentary by Michael Poles MD, Associate Editor, Clinical Correlations 

Welcome back blogophiles to this week’s clinical correlations. Hope you all had a nice President’s Day weekend. Now, let’s move on to the discussion.

I was a bit disturbed last night, while watching 60 minutes on TV. Their first piece was an expose on Bayer’s drug Trasylol (aprotinin), which has been used for 14 years to control bleeding in the OR. This blockbuster drug resulted in earnings of hundreds of millions…

Read more »

Grand Rounds: “Fibromyalgia and Homeopathy: Holmes, Hogwarts and the Prince of Wales”

February 14, 2008
Grand Rounds: “Fibromyalgia and Homeopathy: Holmes, Hogwarts and the Prince of Wales”

Commentary by Nitasha Sarswat MD, PGY-3 

This week’s Medicine Grand Rounds speaker was Gerald Weissmann, MD, a familiar face at Bellevue/NYU. He is a professor of rheumatology, the former chairman of the Department of Rheumatology and current director of the Biotechnology Study Center.

Dr. Weissmann began by discussing homeopathic medicine and its roots in the Romantiic reaction against the Enlightenment and how homeopathic treatments today are not rooted in science. He discussed the use of plants such as briony and rhus toxicodendron…

Read more »

Clinical Pathology Conference 1/08- The Answer

February 13, 2008

Case Presentation by Minisha Sood MD, Chief Resident

Please review the posting of our prior CPC here.

When you’re ready you can download the CPC Answer.

Read more »

Shortcuts-This Week in the Journals

February 11, 2008
Shortcuts-This Week in the Journals

Commentary by Aaron Lord MD, Copy Editor, Clinical Correlations

The medical news event of the week was of course the early termination of the glucose control arm of the ACCORD trial, which showed increased mortality with intensive glucose control. You can check it out via our post on the trial by Endocrinology Section Editor Melissa Freeman.  Also, make sure to eyeball Goede’s et al. study in this week’s NEJM which showed decreased mortality with intensive glucose control.  Stay tuned as this interesting story…

Read more »

A New Path for the ACCORD (The Action to Control Cardiovascular Risk in Diabetes) trial: Does Being Sweeter Save Lives?

February 8, 2008
A New Path for the ACCORD (The Action to Control Cardiovascular Risk in Diabetes) trial: Does Being Sweeter Save Lives?

Commentary by Melissa Freeman MD, Endocrinology Section Editor

The ACCORD trial is an ongoing 5-year, North American, randomized study that began in 2001 to evaluate potential interventions to decrease cardiovascular (CV) events in adults living with DM2.  The trial enrolled 10,251 adults, aged 40- 82, with DM2 for 10 or more years, and a history of CV disease or two CV risk factors in addition to DM2. All participants were randomized at enrollment into intensive versus standard glucose control. In addition, participants were…

Read more »